|Page (1) of 1 - 09/13/17||email article||print page|
(September 13, 2017)
DUBLIN--(BUSINESS WIRE)--The "Global Solid Tumor Therapeutics Market - Growth, Trends and Forecast 2017 - 2022" report has been added to Research and Markets' offering.
According to WHO, around 8 million people died with various forms of cancer around the world in 2012, the number of new cases is expected to rise by about 70% over the next 2 decades. North America and Europe holds the top two positions in solid tumor therapeutics market due to high incidence rate.
Solid tumor therapeutics are pharmaceuticals that specifically treat various cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer and others. Solid tumors are an abnormal mass of tissue that usually does not contain cysts or liquid areas. Market analysis in this report provides insight on major players in solid tumor therapeutics that are operating in the market. It helps the new players to understand the business models and identify the product lines of the specific companies to establish in solid tumor therapeutics market. The increasing investment in R&D of therapeutics, increasing expenditure in healthcare, unmet need for efficacious drug and growing competition for new drugs are key factors propelling the growth of the market. However, increasing cost of R&D, drugs going off patent, increasing generic products, and high cost of therapy are turning out to be restraints for the market.
The solid tumor therapeutics market has been segmented based on the type of cancer, drugs and geography. The solid tumor therapeutics have been segmented based on the type of cancer and it is classified into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer and others. The segment of drugs are as follows: Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Doxorubicin, Bevacizumab (Avastin), Erlotinib (Tarceva), Sunitinib (Sutent), Everolimus (Afinitor), Docetaxel (Taxotere), Abiraterone acetate (Zytiga), Cabazitaxel (Jevtana) and others.
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd.
- Biogen Idec, Inc.
- Boehringer Ingelheim GmbH
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Eli Lilly and Company
- Kyowa Hakko Kirin Co., Ltd.
- Amgen, Inc.
- Baxter International, Inc.
- Abbott Laboratories, Inc
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
6. Drivers, Restraints, Opportunities and Challenges Analysis
7. Global Solid Tumour Therapeutics Market Segmentation
8. Global Psoriasis disease drug market by Geography - Regional shares and forecast
9. Competitive Landscape
10. Company Profiles
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
For more information about this report visit https://www.researchandmarkets.com/research/r373hf/global_solid
Research and Markets
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs
Related Sites: DMN Newswire , itbusinessnet.com , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , IBN - IT Weekly Newsletter , DMN Newswire Newsletter